Indivior PLC (INVVY) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 North Chesterfield, VA, 미국. 현재 CEO는 Mark Crossley.
INVVY 을(를) 보유 IPO 날짜 2015-06-09, 1,000 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $3.01B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing medications for opioid use disorder and related mental health conditions. The company markets several buprenorphine-based prescription drugs, including SUBLOCADE, a subcutaneous injection, and the SUBOXONE and SUBUTEX sublingual formulations, alongside legacy products such as Temgesic and Buprenex. With operations across approximately 40 countries and a pipeline addressing opioid addiction and schizophrenia, Indivior combines established product revenues with research collaborations to advance treatment options in addiction medicine. Incorporated in 2014 and headquartered in North Chesterfield, Virginia, the company serves patients and healthcare providers globally.
